Russian Ministry of Health has approved Sava Healthcare’s DPI capsules manufacturing line for respiratory therapeutic segment
Sava Healthcare, which specialises in manufacture and marketing of nasal sprays and Dry Powder Inhalers (DPI), announced that the Russian Ministry of Health (MOH) Minzdrav Rossii has approved its DPI capsules manufacturing line for respiratory therapeutic segment. This will strengthen SAVA’s presence in the Russian and CIS region.
SAVA’s Surendranagar facility is also accredited by HEALTH CANADA, PICs Ukraine, WHO-GMP, amongst other Drug Administration authorities. SAVA has developed latest generations DPIs like Tiotropium, Formeterol, salmeterol/ fluticasone, Budesonide/ Formeterol Fumarate for Russian and other CIS markets. DSIR approved in-house R&D Center of SAVA at Pune (India) is well-equipped Formulations R&D centre catering to Dry Powder Inhalers (DPI) development and has best in class R&D equipment like Dosage Unit Sampling apparatus (DUSA), Next Gen Impactor (NGI) and Glass Twin Impinger (T1, T2).